Resurrecting DNAzymes as sequence-specific therapeutics.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. A modular XNAzyme cleaves long, structured RNAs under physiological conditions and enables allele-specific gene silencing.Nature chemistry · 2022
   Article
2. Antiangiogenic and antitumoral effects mediated by a vascular endothelial growth factor receptor 1 (VEGFR-1)-targeted DNAzyme.Molecular medicine (Cambridge, Mass.) · 2013
   Article
3. Destroying c-jun Messenger: new insights into biological mechanisms of DNAzyme function.Oncotarget · 2012
   Article

Corrections and comments

• Comment on
  DNAzyme targeting c-jun suppresses skin cancer growth.2012

Authors and funding

1 author.

Funding

Abstract

Indexed as